Compare Fresenius Kabi Onco. with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs AJANTA PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. AJANTA PHARMA FRESENIUS KABI ONCO./
AJANTA PHARMA
 
P/E (TTM) x 22.1 21.4 103.3% View Chart
P/BV x 3.1 3.8 82.4% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 FRESENIUS KABI ONCO.   AJANTA PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
AJANTA PHARMA
Mar-19
FRESENIUS KABI ONCO./
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,422 12.4%   
Low Rs79898 8.7%   
Sales per share (Unadj.) Rs37.7233.5 16.1%  
Earnings per share (Unadj.) Rs5.144.0 11.6%  
Cash flow per share (Unadj.) Rs6.752.2 12.9%  
Dividends per share (Unadj.) Rs09.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5255.1 16.7%  
Shares outstanding (eoy) m158.2388.02 179.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.45.0 68.0%   
Avg P/E ratio x25.026.4 94.7%  
P/CF ratio (eoy) x18.922.2 85.1%  
Price / Book Value ratio x3.04.5 65.8%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m20,135102,081 19.7%   
No. of employees `0001.26.8 16.9%   
Total wages/salary Rs m7034,307 16.3%   
Avg. sales/employee Rs Th5,176.23,022.6 171.3%   
Avg. wages/employee Rs Th610.4633.4 96.4%   
Avg. net profit/employee Rs Th699.6569.1 122.9%   
INCOME DATA
Net Sales Rs m5,96320,554 29.0%  
Other income Rs m18211 8.5%   
Total revenues Rs m5,98120,765 28.8%   
Gross profit Rs m1,4305,664 25.2%  
Depreciation Rs m258721 35.8%   
Interest Rs m-2612 -224.1%   
Profit before tax Rs m1,2165,143 23.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,273 26.9%   
Profit after tax Rs m8063,870 20.8%  
Gross profit margin %24.027.6 87.0%  
Effective tax rate %28.124.8 113.7%   
Net profit margin %13.518.8 71.8%  
BALANCE SHEET DATA
Current assets Rs m5,10211,812 43.2%   
Current liabilities Rs m2,3853,776 63.2%   
Net working cap to sales %45.639.1 116.5%  
Current ratio x2.13.1 68.4%  
Inventory Days Days15077 193.9%  
Debtors Days Days11382 138.8%  
Net fixed assets Rs m5,14814,398 35.8%   
Share capital Rs m158175 90.2%   
"Free" reserves Rs m6,55622,277 29.4%   
Net worth Rs m6,73222,452 30.0%   
Long term debt Rs m9527 14,427.3%   
Total assets Rs m10,38826,962 38.5%  
Interest coverage x-45.8444.3 -10.3%   
Debt to equity ratio x0.10 48,118.3%  
Sales to assets ratio x0.60.8 75.3%   
Return on assets %7.514.4 52.2%  
Return on equity %12.017.2 69.5%  
Return on capital %14.623.0 63.6%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29810,682 49.6%   
Fx outflow Rs m1,7722,102 84.3%   
Net fx Rs m3,5258,580 41.1%   
CASH FLOW
From Operations Rs m1,2743,748 34.0%  
From Investments Rs m-1,204-2,228 54.0%  
From Financial Activity Rs m-196-1,475 13.3%  
Net Cashflow Rs m-12645 -279.4%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 1.6 19.4%  
FIIs % 9.6 7.6 126.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.0 53.5%  
Shareholders   42,599 20,968 203.2%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS